Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25479152 | 1.00 | TSHR (0.39) | TSHRRECQLGLP1RALDH1A1MEN1 | |
| SCHEMBL24672702 | 0.91 | TSHR (0.40) | TSHRRECQLGLP1RALDH1A1MEN1 | |
| SCHEMBL22526077 | 0.91 | TSHR (0.40) | TSHRRECQLGLP1RALDH1A1MEN1 | |
| SCHEMBL24673317 | 0.91 | TSHR (0.40) | TSHRRECQLGLP1RALDH1A1MEN1 | |
| SCHEMBL25123586 | 0.90 | TSHR (0.40) | TSHRRECQLGLP1RALDH1A1FAAH | |
| SCHEMBL23945414 | 0.88 | HPGD (0.40) | TSHRRECQLALDH1A1MEN1KMT2A | |
| SCHEMBL25122630 | 0.87 | TSHR (0.47) | TSHRRECQLGLP1RALDH1A1FAAH | |
| SCHEMBL25123197 | 0.87 | TSHR (0.47) | TSHRRECQLGLP1RALDH1A1FAAH | |
| SCHEMBL22794325 | 0.87 | TSHR (0.50) | TSHRRECQLGLP1RALDH1A1FAAH | |
| SCHEMBL24514221 | 0.87 | TSHR (0.50) | TSHRRECQLGLP1RALDH1A1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885RECQL 2866/4885GLP1R 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.